Sign Up to like & get
recommendations!
0
Published in 2019 at "Hepatology"
DOI: 10.1002/hep.30222
Abstract: Treatment of hematological malignancy with antibody‐drug conjugates (ADCs) may cause liver injury. ADCs deliver a toxic moiety into antigen‐expressing tumor cells, but may also injure hepatic sinusoids (sinusoidal obstruction syndrome; SOS). We studied patients who…
read more here.
Keywords:
treatment;
anti cd22;
liver;
malignancy ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.16871
Abstract: B-cell lymphoma accounts for approximately 85% of all adult non-Hodgkin's lymphoma cases. Doxorubicin (DOX) is an indispensable drug for the treatment of non-Hodgkin's lymphoma. However, DOX causes severe cardiotoxicity, which limits its use in conventional…
read more here.
Keywords:
lymphoma treatment;
cd22;
treatment;
anti cd22 ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "OncoTargets and therapy"
DOI: 10.2147/ott.s255629
Abstract: [This corrects the article DOI: 10.2147/OTT.S235882.].
read more here.
Keywords:
infusion anti;
anti cd22;
anti;
sequential infusion ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2022 at "Antibodies"
DOI: 10.3390/antib11030053
Abstract: Since they lack native soluble membrane antigens, the analysis and selection of antigen-specific antibodies are commonly performed on whole live cells. Here, we have developed a simple and convenient enzyme-linked immunosorbent assay (ELISA) based on…
read more here.
Keywords:
antibodies cell;
anti cd22;
therapeutic anti;
cd22 monoclonal ... See more keywords